Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Byetta | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Pharmaceuticals | Study